Fig. 1: Growth inhibition in ovarian cancer cell lines by SRA737 and adavosertib in-vitro and in-vivo. | BJC Reports

Fig. 1: Growth inhibition in ovarian cancer cell lines by SRA737 and adavosertib in-vitro and in-vivo.

From: Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models

Fig. 1

a Colony formation assays when cells were exposed to 1xSF50, adavosertib and SRA737 as single agents and in combination for 14 days, n = 3. There was significant reduction in colony formation of the samples exposed to combination compared to control in OVCAR3 and MDA-MB-436 cell lines p = <0.0001 and p = 0.0006 respectively. b In vivo evaluation of the combination of adavosertib and SRA737. Mice were treated with oral doses of adavosertib 75 mg/kg BD and SRA737 120 mg/kg QD on day 0,1,7,8,14,15,21 and 22. In the OVCAR-3 xenograft model There was a statistically significant difference in tumor volumes between the control arm and combination therapy arm p < 0.0001 on day 28. In the MDA-MB-436 xenograft model, there was a statistically significant difference in tumor volumes between the control arm and the combination therapy arm p = 0.0025 on day 28.

Back to article page